Iryna Drozd DURECT ( NASDAQ: DRRX ) has received FDA breakthrough therapy designation for its drug candidate larsucosterol in the treatment of severe alcohol-related hepatitis. The drug developer plans to present additional details on Phase 2 data for the drug at the upcoming European Association for the Study of the Liver Congress, to be held in Milan on June 8, according to a statement . More on DURECT DURECT Corporation (DRRX) Q1 2024 Earnings Call Transcript DURECT Corporation (DRRX) Q4 2023 Earnings Call Transcript DURECT Q1 2024 Earnings Preview DURECT and Charles River enter agreement for alzet in U.
S., Canada Seeking Alpha’s Quant Rating on DURECT.
